These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Toll or toll-free adjuvant path toward the optimal vaccine development. Ishii KJ; Akira S J Clin Immunol; 2007 Jul; 27(4):363-71. PubMed ID: 17370119 [TBL] [Abstract][Full Text] [Related]
6. Precision nanoscale patterning of TLR ligands for improved cancer immunotherapy. Tseng CY; Murtada F; Chou LYT Cell Rep Methods; 2024 May; 4(5):100782. PubMed ID: 38772343 [TBL] [Abstract][Full Text] [Related]
7. Immune adjuvants in early life: targeting the innate immune system to overcome impaired adaptive response. de Brito CA; Goldoni AL; Sato MN Immunotherapy; 2009 Sep; 1(5):883-95. PubMed ID: 20636030 [TBL] [Abstract][Full Text] [Related]
8. Toll-like receptor ligands energize peptide vaccines through multiple paths. Celis E Cancer Res; 2007 Sep; 67(17):7945-7. PubMed ID: 17804699 [TBL] [Abstract][Full Text] [Related]
9. [Development of Nucleic Acid-Based Adjuvant for Cancer Immunotherapy]. Kobiyama K; Ishii KJ Gan To Kagaku Ryoho; 2015 Sep; 42(9):1040-5. PubMed ID: 26469159 [TBL] [Abstract][Full Text] [Related]
11. Vaccine adjuvants as potential cancer immunotherapeutics. Temizoz B; Kuroda E; Ishii KJ Int Immunol; 2016 Jul; 28(7):329-38. PubMed ID: 27006304 [TBL] [Abstract][Full Text] [Related]
12. Adjuvants and autoimmunity. Israeli E; Agmon-Levin N; Blank M; Shoenfeld Y Lupus; 2009 Nov; 18(13):1217-25. PubMed ID: 19880572 [TBL] [Abstract][Full Text] [Related]
13. Cancer immunotherapy and nanomedicine. Sheng WY; Huang L Pharm Res; 2011 Feb; 28(2):200-14. PubMed ID: 20821040 [TBL] [Abstract][Full Text] [Related]
14. Cancer Vaccines: Adjuvant Potency, Importance of Age, Lifestyle, and Treatments. Cuzzubbo S; Mangsbo S; Nagarajan D; Habra K; Pockley AG; McArdle SEB Front Immunol; 2020; 11():615240. PubMed ID: 33679703 [TBL] [Abstract][Full Text] [Related]
15. Vaccine Strategies to Improve Anti-cancer Cellular Immune Responses. Vermaelen K Front Immunol; 2019; 10():8. PubMed ID: 30723469 [TBL] [Abstract][Full Text] [Related]
16. Applications of chemokines as adjuvants for vaccine immunotherapy. Mohan T; Zhu W; Wang Y; Wang BZ Immunobiology; 2018; 223(6-7):477-485. PubMed ID: 29246401 [TBL] [Abstract][Full Text] [Related]
17. Targeting CpG Adjuvant to Lymph Node via Dextran Conjugate Enhances Antitumor Immunotherapy. Zhang W; An M; Xi J; Liu H Bioconjug Chem; 2017 Jul; 28(7):1993-2000. PubMed ID: 28644608 [TBL] [Abstract][Full Text] [Related]
18. [Toll-like receptors: recognition receptors of the innate immune system and target structures for therapeutical intervention]. Kabelitz D Med Monatsschr Pharm; 2012 Jul; 35(7):238-44. PubMed ID: 22852274 [TBL] [Abstract][Full Text] [Related]
19. The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. Smits EL; Ponsaerts P; Berneman ZN; Van Tendeloo VF Oncologist; 2008 Aug; 13(8):859-75. PubMed ID: 18701762 [TBL] [Abstract][Full Text] [Related]
20. A cancer vaccine based on fluorine-modified sialyl-Tn induces robust immune responses in a murine model. Song C; Zheng XJ; Liu CC; Zhou Y; Ye XS Oncotarget; 2017 Jul; 8(29):47330-47343. PubMed ID: 28537884 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]